MeiraGTx Holdings PLC (MGTX) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to a loss of $0.62 per share a year ago.
MeiraGTx's reported profitability in 2026Q2, with revenue of $321.4M and net income of $160.7M, appears to reflect a single milestone recognition event rather than recurring commercial demand, as the company posted a -$51.2M net loss in 2026Q3 and operating cash outflow of -$38.5M in the same prior quarter.
Price trend, volume and key moving averages
Trailing total returns as of 11/17/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 12, 2026 | -$0.53-6.0% vs -$0.50 | $5M-30.8% vs $7M |
Q3 2026 Aug 13, 2026 | $1.71+473.1% vs -$0.46 | $321M+45819.1% vs $700,000 |
Q2 2026 May 14, 2026 | -$0.57-32.6% vs -$0.43 | $293,000-98.3% vs $17M |
Q2 2026 Mar 26, 2026 | $0.19+131.7% vs -$0.60 | $75M+5115.3% vs $1M |
MeiraGTx Holdings PLC (MGTX) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to a loss of $0.62 per share a year ago.
Submission of Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP) expected in December 2026 Submission of full Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for bota-vec expected in the first quarter of 2027 12-month data readout in pivotal Phase 2 AQUAx2 study of AAV2-hAQP1 for the treatment of radiation-induced xerostomia (RIX) mid-2027 Upcoming oral presentation at ObesityWeek highlights AAV-BDNF program for the treatment of MC4R/BDNF genetic obesity (severe early-onset syndromic obesity) Strengthened leadership with the appointment of John Knighton as Executive Vice President of Global Manufacturing and Supply Chain and Alan M. Sebulsky to the Board of Directors LONDON and NEW YORK, Nov. 12, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced financial and operational results for the third quarter ended September 30, 2026, and provided a corporate update.
Multiple Posters Highlight the Breadth of Company's Novel Genetic Medicine and Cell Therapy Platforms Multiple Posters Highlight the Breadth of Company's Novel Genetic Medicine and Cell Therapy Platforms
MeiraGTx (NASDAQ: MGTX - Get Free Report) and aTyr Pharma (NASDAQ: ATYR - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends. Valuation and Earnings This table compares MeiraGTx and
Benchmark MGTX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for MeiraGTx Holdings plc (MGTX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $8.74 | $809.41M | 10.82 | 144.57% | 19.48% | 85.3% | — | |
| $0.77 | $262.13M | -4.01 | 8.83% | -1367.61% | — | — | |
| $1.87 | $286.97M | -3.98 | 25.39% | -144.95% | -130.43% | — | |
| $40.37 | $3.89B | -8.56 | -89.97% | -1812.07% | -25.59% | — | |
| $9.86 | $1.11B | -3.24 | 16.92% | -805.75% | -64.73% | — | |
| $20.94 | $2.15B | -20.47 | 120.01% | -73.04% | -9.69% | — |
MeiraGTx Holdings plc (MGTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
MeiraGTx Holdings plc (MGTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 12, 2026·SEC
Aug 13, 2026·SEC
Jul 7, 2026·SEC
Get notified when MGTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MeiraGTx Holdings plc (MGTX) stock FAQ — growth, dividends, profitability & financials explained
MeiraGTx Holdings plc (MGTX) reported $401.9M in revenue over the trailing twelve months. Revenue was $81.4M in fiscal year 2025.
MeiraGTx Holdings plc (MGTX) grew revenue by 1365.9% over the trailing twelve months, compared with the twelve months before.
Yes. MeiraGTx Holdings plc (MGTX) earned $78.3M in net income over the trailing twelve months (a 19.5% net margin).
MeiraGTx Holdings plc (MGTX) had a return on equity (ROE) of 85.3% over the trailing twelve months. That is well above the market's typical 10-15%.
MeiraGTx Holdings plc (MGTX) had negative free cash flow of $9.5M over the trailing twelve months.